Group ID|Group Name|Treatment Sequence|Treatment Age|Treatment Type|Treatment Quantity|Treatment Unit|Treatment Application|Treatment Remarks|No of individuals in study|Species|Strain|Sex|Age|Group Endpoints|Individual ID|Group ID|Age at death|Pathology type|Pathology location|Pathology Description|
17-5-1|n/a,n/a|1|600|X-rays whole body|11.7|grays|External exposure local|upper body =72% of bone marrow dogs aged 16-24 months|3 (0 in ERA)|Dog|Dog, Beagle|Both|Young Adult|haematological parameters, bone marrow GM-CFC, CFU-F serum CSA sequential studies over one year|No information on individuals available for this study
17-5-2|n/a,n/a|1|600|X-rays whole body|11.7|grays|External exposure local|lower body =28% of bone marrow, dogs aged 16-24 months|6 (0 in ERA)|Dog|Dog, Beagle|Both|Young Adult|haematological parameters, bone marrow GM-CFC, CFU-F serum CSA sequential studies over one year|No information on individuals available for this study
